Odyssean LLC Makes New Investment in Medpace Holdings, Inc. $MEDP

Odyssean LLC purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 6,361 shares of the company’s stock, valued at approximately $3,369,000. Medpace comprises 0.5% of Odyssean LLC’s investment portfolio, making the stock its 12th biggest position.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Johnson Financial Group Inc. purchased a new position in Medpace in the 2nd quarter worth about $27,000. Elyxium Wealth LLC purchased a new stake in shares of Medpace during the 4th quarter valued at about $30,000. Jones Financial Companies Lllp purchased a new stake in Medpace in the second quarter worth approximately $30,000. Allied Private Wealth LLC bought a new stake in shares of Medpace in the second quarter worth $31,000. Finally, Kilter Group LLC bought a new position in Medpace in the second quarter valued at about $31,000. 77.98% of the stock is owned by institutional investors.

Medpace Trading Down 0.4%

Shares of NASDAQ:MEDP opened at $591.29 on Friday. The stock has a 50 day moving average of $574.67 and a 200 day moving average of $499.52. The company has a market cap of $16.50 billion, a PE ratio of 34.66, a price-to-earnings-growth ratio of 2.65 and a beta of 1.15. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO August Troendle sold 650 shares of Medpace stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $620.27, for a total transaction of $403,175.50. Following the transaction, the chief executive officer owned 539,894 shares in the company, valued at approximately $334,880,051.38. The trade was a 0.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kevin Brady sold 3,400 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $625.24, for a total transaction of $2,125,816.00. Following the completion of the transaction, the chief financial officer directly owned 12,830 shares of the company’s stock, valued at $8,021,829.20. This represents a 20.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 134,471 shares of company stock valued at $82,151,311 over the last 90 days. Company insiders own 20.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on MEDP. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Mizuho upped their target price on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and lifted their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Finally, TD Cowen boosted their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $595.20.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.